MicroRNA-9 Enhanced Cisplatin Sensitivity in Nonsmall Cell Lung Cancer Cells by Regulating Eukaryotic Translation Initiation Factor 5A2

Figure 2

MiR-9 overexpression enhances NSCLC cell sensitivity to cisplatin. (a) CCK-8 examination of cell viability following treatment with cisplatin alone or with cisplatin plus miR-9 mimic or inhibitor. (b, c) EdU staining analysis of cell proliferation following treatment with cisplatin alone or with cisplatin plus miR-9 mimic or inhibitor. < 0.05, < 0.01 vs. cisplatin; ##P < 0.01 vs. cisplatin+miR-9 mimic. (d) Flow cytometry determination of the percentage of apoptotic cells following treatment with cisplatin alone or with cisplatin plus miR-9 mimic or inhibitor. < 0.05, < 0.01, and < 0.001.

(a)

(b)

(c)

(d)